Alzheimer's Preparation Shows Benefit

Donepezil (Aricept) shown to benefit patients over 50 with severe impairment...The selective acetylcholine esterase inhibitor donepezil provides greater improvements in cognition and global function than placebo in patients who have severe Alzheimer's disease (AD) and reside in the community or in assisted-living facilities. Donepezil is also well tolerated and provides benefits throughout the course of AD.

This multinational, randomised, double-blind, placebo-controlled trial was presented at the 10th Congress of the European Federation of Neurological Societies (EFNS) on behalf of the authors by Elias Schwam, PhD, senior clinical director, Worldwide Alzheimer's Team, Pfizer Inc., New York, New York

This page is powered by Blogger. Isn't yours?